News | December 05, 2014

Research Uncovers new way to Help Predict Outcomes for TAVR Patients

A retrospective analysis from the Minneapolis Heart Institute Foundation reveals that tricuspid regurgitation (TR) can help doctors predict which patients may have poor outcomes from the TAVR procedure

Clinical Trial, Heart valve repair, TAVR

December 5, 2014 – An estimated quarter of a million of older adults are diagnosed with aortic valve stenosis each year. And the treatment options, which include open-heart surgery to replace the aortic valve and less invasive transcatheter aortic valve replacement (TAVR), come with serious risks as well, including death.

New research from the Minneapolis Heart Institute Foundation has uncovered a way to help interventional cardiologists better predict which patients are at higher risk for death following TAVR, allowing both patient and surgeon to discuss a potentially different treatment plan.

Cardiologists and heart surgeons already look closely at tricuspid regurgitation (TR) in patients who are candidates for surgical aortic valve replacement, because the condition can tell them how likely the patient is to benefit from the procedure. This new research shows that TR may help cardiologists identify patients who are good (or poor) candidates for the minimally invasive TAVR procedure too.

To assess the impact of TR on TAVR outcomes, MHIF researchers analyzed the medical records of 129 TAVR patients. They looked at TR both before the procedure (baseline) and 30 days after, and classified the condition as none, mild, moderate or severe. The cases were divided into two groups according to baseline TR: none (n=89) and significant (anything worse than mild) (n=32). Survival following TAVR was significantly worse both in patients with significant TR and in patients who developed late TR (TR that had worsened to either moderate or severe at 30 days follow-up). The results were independent of baseline left ventricular ejection fraction (LVEF).

“While we don’t know yet whether this is cause and effect or TR is simply a marker for poor heart function,” said co-researcher Robert Schwartz, M.D., FACC, FAHA, “TR status and severity should be included in TAVR risk assessments to guide treatment decisions and aid in prognosis.”

For more information: www.mplsheart.org

Related Content

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
Overlay Init